Introduction {#Sec1}
============

The intrauterine device (IUD) is a popular and effective form of contraception used by approximately 14% of women globally^[@CR1]^. Commonly used IUDs include a hormonal IUD that releases levonorgestrel (LNG-IUS), and a non-hormonal copper IUD (cu-IUD) that releases copper ions. The contraceptive efficacy of IUDs has been attributed in part to their effects as foreign bodies that induce local inflammation; in addition, the cu-IUD and LNG-IUS have direct toxic effects on sperm and the LNG-IUS also causes endometrial atrophy and alterations in cervical mucus rendering it unfavorable to sperm penetration^[@CR2]--[@CR5]^.

We recently studied the local immune microenvironment in the upper female reproductive tract of LNG-IUS users compared to mid-luteal samples from women not using hormonal or intrauterine contraceptives^[@CR6],[@CR7]^. We found that the endometrial transcriptome from LNG-IUS users was associated with pronounced signals of inflammation consistent with a foreign body reaction^[@CR7]^. These findings could be due to the presence of a foreign body (the IUD), the effect of LNG released by the IUD, or both. The purpose of this study was to compare the independent and combined effects of LNG exposure and IUD exposure on the transcriptome of the upper female reproductive tract, in order to better understand potential mechanisms of contraceptive action by these different methods.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a cross-sectional study comparing transcriptomes from the endometrium or cervical transformation zone (TZ) from samples donated by 4 groups of women using: no hormonal or intrauterine contraception (controls), cu-IUD (Paragard T 380 A, Cooper Surgical, Trumbull CT), LNG-IUS (Mirena, Bayer Healthcare Pharmaceuticals Inc, Finland) or LNG-containing COC. The UCSF Human Research Protection Program & IRB approved the study protocol, recruiting and consent materials; all procedures were performed in accordance with these regulations.

Study procedures {#Sec4}
----------------

Methods for the recruitment, screening and sample collection are described in detail elsewhere^[@CR8]^; participants whose samples contributed to this study had sufficient amounts of appropriate endometrial and/or cervical tissue. Briefly, healthy women volunteers age 18--45 years were recruited from the San Francisco Bay Area. Participants in the COC group had to be using a cyclic 28-day pill pack of ethinyl estrogen plus LNG containing either 0.10 or 0.15 mg of LNG per tablet. Participants in the control and cu-IUD groups had to have regular periods every 21--35 days. Exclusion criteria included hysterectomy, breast-feeding, being within 6 months of parturition, having abnormal cervical cytology in the past year, and use of systemic corticosteroids or immune‐modulating therapies. At the screening visit, written informed consent was obtained from all participants, urine was tested for pregnancy, *Chlamydia trachomatis* and *Neisseria gonorrheae*, and blood was tested for HIV serology; a positive result or clinical evidence of vaginitis, vaginosis or pelvic inflammatory disease resulted in exclusion. At the second study visit, participants were given kits and instructions for urine testing for luteinizing hormone (LH) (ClearBlue Ovulation Test Digital, Proctor and Gamble, Cincinnati, OH). Women in the control and cu-IUD groups underwent biopsies 7 to 11 days after a positive LH test result. Women using the LNG-IUS underwent biopsies 7 to 11 days after a positive LH test or at their convenience after 2 months with no positive result, whichever came first. COC users underwent biopsies on day 12--16 of their pill pack.

For sample collection, the posterior vaginal fornix was swabbed with Q-tips for measurement of pH and prostate specific antigen (Abacus Diagnostics, West Hills, CA), a marker of recent vaginal intercourse; pH \> 6.0 or positive PSA test led to exclusion of the sample from analysis. Endometrial biopsy was obtained with a 3 mm biopsy cannula (Softflex Endometrial Biopsy Cannula, Integra Miltex, York PA) and tissue was collected with 1 or 2 passes. A biopsy with Tischler forceps was performed at the cervical TZ, identified as the junction between Lugol's staining and non-staining epithelium; if the TZ was not seen, the biopsy was obtained with one of the biopsy prongs inside the os. Blood was collected for measurement of plasma progesterone level. Endometrial and cervical biopsies were snap frozen and stored at −80 degrees until analysis.

RNA Extraction and Whole Genome Microarrays {#Sec5}
-------------------------------------------

Biopsy samples were minced into small fragments and total RNA was extracted and DNase-treated using the NuceloSpin RNA II Kit (Marcherey-Nagel Inc, Bethlehem, PA). RNA quality was assessed using Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and quantity and purity determined with a NanoDrop Spectrometer. The NuGen Pico V2, based on Ribo-SPIA technology, was used for amplification, fragmentation and biotin-labelling and the labeled cDNA was hybridized to Human Gene 1.0 microarrays (Affymetrix, Santa Clara, CA) at the UCSF Gladstone Institutes Genomics Core. The signal intensity fluorescent images produced during the Affymetrix GeneChip hybridizations were read using the Affymetrix Model 3000 Scanner and converted into GeneChip probe results files (cel) using Command and Expression Console software (Affymetrix).

Gene expression data processing and statistical analysis {#Sec6}
--------------------------------------------------------

The analyses were performed separately comparing each of the contraceptive groups with the control group for the cervical and the endometrial samples. The raw cel files were read using the *read.celfiles* function that is part of the oligo package^[@CR9]^ in bioconductor^[@CR10]^. The probes were matched to their corresponding gene symbols and ensembl ids using the annotate^[@CR11]^ and hugene10sttranscriptcluster.db^[@CR12]^ packages. The expression of all genes were normalized across all the samples in the chosen contraceptive and control group using the Robust Multi-array Average (RMA) procedure^[@CR13]^. The top 500 most variable (across all samples) genes were chosen using these normalized data. The data corresponding to these 500 genes were used to perform Principal Component Analyses (PCA) using the *prcomp* function in R^[@CR14]^. The association of the expression of genes with the particular contraceptive use was estimated using the bioconductor package limma^[@CR15]^. Due to potential confounding due to the age of the subjects, age was adjusted as a linear term in the (limma) models associating expression of each gene with contraceptive use. The p-values reported by limma are adjusted for multiple testing using the False Discovery Rate (FDR) procedure^[@CR16]^. The raw cel files discussed in this publication have been deposited in NCBI's Gene Expression Omnibus^[@CR17]^ and are accessible through GEO Series accession number GSE137765.

Gene ontology and pathway analysis {#Sec7}
----------------------------------

The list of differentially expressed genes with adjusted p ≤ 0.05 were entered into EnrichR, a gene list enrichment analysis tool^[@CR18],[@CR19]^ and the Pathways analysis produced by Reactome 2016^[@CR20]^. The outputs displaying pathways ranked by combined score, a calculation based on the p-value and the Z score \[log(p)•z\], were chosen for presentation here.

Results {#Sec8}
=======

Characteristics of study participants {#Sec9}
-------------------------------------

Table [1](#Tab1){ref-type="table"} demonstrates the demographic characteristics of participants who donated endometrial samples to the study. The control group was significantly older than the IUD and COC users, hence the gene expression association analyses presented below are adjusted for age as described above. The groups did not otherwise differ with respect to race, ethnicity, education, or smoking history. For endometrial samples, the median progesterone level (ng/ml) in the control group was 10.8 (range 5.8--18.6) and in the cu-IUD group was 11.2 (5.7--27.8), confirming that the participants in these groups were in the luteal phase. The median progesterone level (ng/ml) in the LNG-IUS group was 3.0 (\<0.5--14.3) and 4 of 11 (36%) had values \>2 indicating ovulation. None of the participants in the COC group had measurable progesterone levels, consistent with the known suppression of ovulation by COCs. The median length of contraceptive exposure was 25 (range 9--42) months for COC, 17 (7--36) months for LNG-IUS and 23 (6--45) months for cu-IUD.Table 1Demographic characteristics of participants who contributed endometrial samples to the study.Control (n = 11)COC (n = 12)LNG-IUS (n = 11)Cu-IUD (n = 13)P valueAge, median (min, max)32(25,46)24(19,33)26(20,41)28(22,33)0.002\*Race, Number (%)   Asian1(9.1)4(33.3)1(9.1)3(23.1)0.99^§^   Black/African American5(45.4)1(8.3)00   Other/2 or more1(9.1)2(16.7)1(9.1)1(7.7)   Unknown01(8.3)1(9.1)1(7.7)   White4(36.4)4(33.3)8(72.7)8(61.5)Ethnicity, Number (%)0.55^§^   Latino3(27.3)1(8.3)3(27.3)4(30.8)   Non-Latino8(72.7)11(91.7)8(72.7)9(69.2)   Unknown0000Education, Number (%)0.77^§^   Some high school or college3(27.3)4(33.3)3(27.3)2(15.4)Finished college or   graduate school8(72.7)8(66.7)8(72.7)11(84.6)   Smoking ever, Number (%)3(27.3)02(18.2)1(7.7)0.18^§^COC combined oral contraceptive; LNG-IUS levonorgestrel-releasing intrauterine system; cu-IUD copper IUD.\* ANOVA. ^§^Fisher's exact test.

Effects of contraceptives on gene expression {#Sec10}
--------------------------------------------

Principal component analysis (PCA) of each of the contraceptive groups compared to the control group is shown in Fig. [1](#Fig1){ref-type="fig"}. The cervical PCA plots demonstrate minimal differentiation between control samples and each of the contraceptive groups (Fig. [1top](#Fig1){ref-type="fig"}). In statistical analysis of gene expression using an adjusted p ≤ 0.05 as the threshold, no genes were significantly differentially expressed in cervical samples from women using LNG-IUS, COC or cu-IUD compared to controls. The PCA plot for endometrial samples shows considerable sample separation for LNG-IUS versus control and is suggestive of separation for COC versus control (Fig. [1bottom](#Fig1){ref-type="fig"}); these comparisons are further analyzed below. For cu-IUD users, the PCA plot shows minimal differentiation with controls, and no genes had statistically significant differential expression in cu-IUD users compared to controls.Figure 1Principal component analysis. After gene expression was normalized across all the samples in the chosen contraceptive and control group using the Robust Multi-array Average (RMA) procedure^[@CR13]^, the data corresponding to the top 500 most variable genes were used to perform Principal Component Analyses (PCA) using the *prcomp* function in R^[@CR14]^ for samples from cervix (top) and endometrium (bottom).

Effect of LNG-IUS on endometrial gene expression {#Sec11}
------------------------------------------------

There were 2509 genes with significantly altered expression levels (adjusted p ≤ 0.05) in LNG-IUS users compared to control samples a; the top 50 genes are shown in Table [2](#Tab2){ref-type="table"} and the complete list of differentially expressed genes is provided in Supp Table [1](#Tab1){ref-type="table"}.Table 2Top 50 differentially expressed genes in endometrial biopsies from LNG-IUS users compared to controls presented hierarchically by adjusted P value.SymbolGENENAMELog2 Fold ChangeAdjusted P ValueC6orf141chromosome 6 open reading frame 141−2.0936.55E-09MT1Gmetallothionein 1G−3.2866.08E-08MT1Emetallothionein 1E−2.1501.55E-07MT1Fmetallothionein 1F−2.9781.55E-07PHYHIPLphytanoyl-CoA 2-hydroxylase interacting protein like−3.9684.02E-07FAM84Bfamily with sequence similarity 84 member B−2.0397.02E-07CCL2C-C motif chemokine ligand 23.3397.02E-07C9orf152chromosome 9 open reading frame 152−2.3177.22E-07CRISP3cysteine rich secretory protein 3−3.9611.21E-06CWH43cell wall biogenesis 43 C-terminal homolog−2.3712.19E-06MT1Mmetallothionein 1M−3.4462.40E-06MT1Hmetallothionein 1H−3.2992.40E-06IFIT1interferon induced protein with tetratricopeptide repeats 12.0172.40E-06GCNT3glucosaminyl (N-acetyl) transferase 3, mucin type−1.7532.40E-06UPK1Buroplakin 1B−3.4434.63E-06SLC15A1solute carrier family 15 member 1−3.2114.63E-06SLC5A1solute carrier family 5 member 1−1.9444.63E-06IFI44Linterferon induced protein 44 like3.0154.63E-06MT1Lmetallothionein 1L (gene/pseudogene)−2.6884.63E-06HSD17B2hydroxysteroid 17-beta dehydrogenase 2−1.8125.18E-06SLC30A2solute carrier family 30 member 2−1.6276.43E-06PLA2G16phospholipase A2 group XVI−1.5986.43E-06DNAJC15DnaJ heat shock protein family (Hsp40) member C15−1.1731.00E-05MRC1mannose receptor, C type 13.0271.24E-05MRC1mannose receptor, C type 13.0271.24E-05HGDhomogentisate 1,2-dioxygenase−3.0301.33E-05HGDhomogentisate 1,2-dioxygenase−3.0301.33E-05ELMO1engulfment and cell motility 11.7301.42E-05IL20RAinterleukin 20 receptor subunit alpha−2.1571.54E-05GJB1gap junction protein beta 1−1.1721.57E-05FAM177A1family with sequence similarity 177 member A1−1.8341.87E-05DTNAdystrobrevin alpha1.4481.87E-05MANSC1MANSC domain containing 1−1.4692.01E-05TNS1tensin 11.5042.01E-05CLDN4claudin 4−1.4112.01E-05PLXDC2plexin domain containing 21.3252.05E-05PLCB4phospholipase C beta 4−1.9322.19E-05TREM1triggering receptor expressed on myeloid cells 13.1542.19E-05IGFBP1insulin like growth factor binding protein 12.6522.19E-05IL10RAinterleukin 10 receptor subunit alpha2.0222.53E-05SRD5A3steroid 5 alpha-reductase 3−1.4062.58E-05FCGR2BFc fragment of IgG receptor IIb3.2662.58E-05MFSD4Amajor facilitator superfamily domain containing 4A−1.8552.58E-05TPD52L1tumor protein D52-like 1−2.2552.58E-05EPYCepiphycan4.7852.74E-05MT1Xmetallothionein 1×−2.0692.86E-05TCN1transcobalamin 1−3.6233.10E-05WIPF1WAS/WASL interacting protein family member 11.7003.20E-05MX1MX dynamin like GTPase 11.7983.29E-05CTSLcathepsin L2.0273.29E-05

The Reactome pathway categories altered in LNG-IUS users are shown in Table [3](#Tab3){ref-type="table"} and indicate that differentially expressed genes mapped predominantly onto immune and inflammatory pathways. A complete list of pathways that showed altered expression with a combined score (defined in section 2.5 above)\>5 is shown in Supp Table [2](#Tab2){ref-type="table"}.Table 3Pathway categories showing altered expression from Reactome 2016 presented hierarchically by combined score values.Levonorgestrel-releasing intrauterine system versus controlP valueZ scoreCombined scoreImmune system2.91E-34−2.23172.37Hemostasis1.27E-18−2.1488.2Cytokine signaling in Immune system2.15E-16−2.3986.11Innate immune system1.51E-18−2.482.05Platelet activation, signaling and aggregation9.94E-14−2.1263.48Interferon signaling7.82E-14−2.0762.46Adaptive immune system8.64E-12−2.2256.43Interferon gamma signaling1.40E-13−1.7451.35Immunoregulatory interactions between a lymphoid and a non-lymphoid cell4.04E-12−1.9551.26Generation of second messenger molecules1.23E-10−1.8943.22**Combined oral contraceptives versus control**Metallothioneins bind metals7.37E-19−1.8577.15Response to metal ions7.37E-19−1.875.23Metabolism8.92E-07−2.2331.05Acyl chain remodeling of phosphatidylcholine5.31E-04−1.8814.19Acyl chain remodeling of phosphatidylinositol4.60E-03−1.8610.03O-linked glycosylation of mucins8.74E-03−2.029.58Acyl chain remodeling of phosphatidylserine5.19E-03−1.739.1Synthesis and interconversion of nucleotide di-and triphosphates1.11E-02−1.948.75Diseases associated with glycosaminoglycan metabolism1.20E-02−1.98.41Acyl chain remodeling of phosphatidylethanolamine9.42E-03−1.798.36

Given that the samples in the LNG-IUS groups included a combination of those from women who had ovulated and those who had not, we performed a sensitivity analysis to determine the effect of ovulatory status on our findings, by comparing gene expression in LNG-IUS users who had ovulated (n = 4) to controls, all of whom had ovulated. We found 1650 genes being associated with LNG-IUS use versus those in the control group (adjusted p-value \<0.05). The decrease from the original 2509 genes is expected given the lower statistical power to declare significance resulting from the use of a smaller number of samples (n = 4 versus n = 11). There is an overlap of 1390 genes between these two sets of genes, or 84% of genes passing statistical threshold in the reduced number of samples were also in the original list of associated genes. The concordance is also apparent when one associates the estimated fold-changes of the expression of 2509 genes identified using all the data versus the estimated fold-changes of expression of these genes using data for only those LNG-IUS samples who had ovulated (Supplemental Figure). These results indicate that lack of ovulation was not the primary driver of our results in the LNG-IUS group.

Effect of COC on Endometrial Gene Expression {#Sec12}
--------------------------------------------

There were 133 genes with significantly altered expression (adjusted p ≤ 0.05) in COC users compared to control samples; the top 50 genes are shown in Table [4](#Tab4){ref-type="table"} and the complete gene list is provided in Supp Table [3](#Tab3){ref-type="table"}. The Reactome pathway categories that are altered in COC users are shown in Table [3](#Tab3){ref-type="table"} and indicate that the differentially expressed genes mapped predominantly onto pathways involving metal ions and acyl chain remodeling. A complete list of pathways that showed altered expression with a combined score \>5 is shown in Supp Table [4](#Tab4){ref-type="table"}.Table 4Top 50 differentially expressed genes in endometrial biopsies from COC users compared to controls presented hierarchically by adjusted P value.SYMBOLGENENAMELog2 Fold ChangeAdjusted P ValueMT2Ametallothionein 2A−2.4047.33E-05MT1Mmetallothionein 1M−3.4677.33E-05MT2Ametallothionein 2A−2.1989.04E-05MT1JPmetallothionein 1J, pseudogene−2.0300.0002MT1Ametallothionein 1A−2.2320.0002S100PS100 calcium binding protein P−3.6850.0002MT1Fmetallothionein 1F−2.7470.0003MT1Xmetallothionein 1×−2.3710.0003DHCR2424-dehydrocholesterol reductase−1.7160.0003MT1Lmetallothionein 1L (gene/pseudogene)−3.1020.0003MT1HL1metallothionein 1H-like 1−1.7980.0003ATRNL1attractin like 11.7130.0003MT1Gmetallothionein 1G−3.4510.0003MT1Bmetallothionein 1B−1.3940.0003SLC30A2solute carrier family 30 member 2−1.4500.0008MT2Ametallothionein 2A−1.6040.0010MFSD4Amajor facilitator superfamily domain containing 4A−1.9380.0016MT1Hmetallothionein 1H−3.2060.0023MT1Emetallothionein 1E−2.2430.0024AIMP1aminoacyl tRNA synthetase complex interacting multifunctional protein 1−1.8010.0024FABP5fatty acid binding protein 5−1.4970.0024FABP5fatty acid binding protein 5−1.5210.0024SLC5A1solute carrier family 5 member 1−1.7970.0025PLXNC1plexin C11.3530.0025SFNstratifin−0.9950.0026CATSPERBcation channel sperm associated auxiliary subunit beta−2.6080.0029AVPR1Aarginine vasopressin receptor 1A1.4070.0031ANXA2annexin A2−1.0790.0031TMEM154transmembrane protein 154−2.0000.0036STEAP1STEAP family member 1−1.4710.0039BNC2basonuclin 21.3620.0046PLA2G2Aphospholipase A2 group IIA−2.4890.0047DEPDC1BDEP domain containing 1B−1.6920.0055LURAP1Lleucine rich adaptor protein 1 like−1.0260.0063ESR1estrogen receptor 11.4010.0065OTUB2OTU deubiquitinase, ubiquitin aldehyde binding 2−0.7760.0077TRIM5tripartite motif containing 50.7310.0088TC2Ntandem C2 domains, nuclear−1.4930.0088L3MBTL3l(3)mbt-like 3 (Drosophila)0.8280.0111GPX1glutathione peroxidase 1−1.0190.0127ZNF750zinc finger protein 750−1.5640.0128CAPZA2capping actin protein of muscle Z-line alpha subunit 2−1.3090.0129MMP7matrix metallopeptidase 73.0660.0134DPP6dipeptidyl peptidase like 61.6680.0141LPCAT2lysophosphatidylcholine acyltransferase 21.1340.0141CPED1cadherin like and PC-esterase domain containing 11.2300.0141PRELPproline and arginine rich end leucine rich repeat protein0.8010.0141ACACBacetyl-CoA carboxylase beta0.5580.0147FXYD3FXYD domain containing ion transport regulator 3−1.2940.0147RHPN2rhophilin Rho GTPase binding protein 2−1.3960.0147

Discussion {#Sec13}
==========

Our results demonstrate that of the three contraceptive methods examined in this study, the LNG-IUS had the strongest effect on the endometrial transcriptome, resulting in significant alterations in genes regulating immune and inflammatory pathways. These results validate findings previously published by our group in an independent set of samples from LNG-IUS users^[@CR7]^. We performed the present study in part to test the hypothesis that different types of IUDs, as foreign bodies in the uterus, would elicit common changes in the endometrium. Instead, we found that the LNG-IUS resulted in differential expression of 2509 genes, whereas the cu-IUD group showed no effect. This unexpected finding suggests that the predominant driver of the inflammatory signal we observed with LNG-IUS is due to the locally released LNG, and is not a result of a foreign body per se. Previous work has demonstrated that LNG is implicated in oxidative stress and apoptosis, which could contribute to the effects we observed on the endometrial transcriptome^[@CR21],[@CR22]^. To avoid measuring perturbations resulting from the insertion itself, participants were required to have had the IUD for ≥6 months, thus we do not think the transcriptional differences are related to length of use of the device. Previous morphological analyses demonstrated that cu-IUDs cause a foreign body reaction and leukocyte infiltration in the endometrium^[@CR23],[@CR24]^; the fact that we did not see this effect in the global endometrial transcriptome could be due to our analysis sampling a larger surface area of the uterine cavity and containing both endometrium and stroma, which might have blunted the ability to detect the local effect seen previously on immunohistochemistry.

A prior analysis of endometrial RNA expression in users of an inert IUD demonstrated 147 genes that were significantly dysregulated in the first month after IUD insertion^[@CR25]^, whereas our study showed no significantly differentially expressed genes in cu-IUD users with a median use of 23 months. Their study looked at Lippes loop IUD, not cu-IUD; the length of IUD exposure was longer in our study, and hence the effects they observed might be attenuated over time; and the statistical methods used to analyze gene expression were different. In our study, samples from both the control and the cu-IUD groups were obtained in the mid-luteal phase as confirmed by timing the sample collection 7--11 days after the LH surge and by serum progesterone levels \>2 ng/ml at the time of sample collection. Our results suggest that the effects of the cu-IUD on the endometrial transcriptome are subtle and might be dominated by the progesterone effects of the luteal phase.

The effect of COCs on the endometrial transcriptome was intermediate between the cu-IUD and the LNG-IUS. Unlike the LNG-IUS, COCs did not cause changes in inflammatory pathways, however both the LNG-IUS and COCs caused significant downregulation of several members of the metallothionein (MT) gene family. MT has well-documented roles in binding of heavy metals including copper for homeostasis and detoxification, and is increasingly being recognized for its role in immunomodulation, apoptosis and the stress response^[@CR26],[@CR27]^. Exposure to LNG-IUS in women with endometrial hyperplasia resulted in decreased immunohistochemical detection of MT protein^[@CR28]^, consistent with our results showing down-regulation of MT RNA in endometrium in both LNG-exposed groups. Release of copper ions from the cu-IUD is postulated to be an important factor for its contraceptive efficacy through spermicidal effects but we did not observe a change in MT gene expression in the cu-IUD group. The effect on MT gene expression in the LNG-IUS and COC groups, and not in the cu-IUD group, supports a common effect of LNG on the endometrium in users of LNG-containing contraceptives related to the stress response functions of MT genes.

In our previous work, we reported 23 genes with altered expression in cervical biopsies from controls compared to LNG-IUS users^[@CR7]^, whereas in this study we found no significant differences in the cervical transcriptomes. The low number of differentially expressed genes and low fold-change in expression levels (maximum of 2.4-fold) in the prior study indicated a relatively weak effect of LNG-IUS on the cervix^[@CR7]^. We attribute our inability to replicate this finding in the current study to the differences in the statistical methods used including methods for normalization, for comparisons of gene expression, and adjustment for false discovery rate.

This work has several strengths. The parallel processing of samples from 4 groups of women provided a direct comparison of contraceptive transcriptomes that to our knowledge has not previously been performed. In cycling women, we synchronized collection to the mid-luteal phase to limit the effects of cyclical hormonal variation on our assays, and to compare contraceptive effects on the endometrial environment at the time of implantation. The rigorous methodology for statistical comparison of gene expression resulted in the detection of robust differences between the groups. Our study also has limitations. The control group was older than the other groups, resulting in adjustment for age in the analysis. Our sample sizes were relatively small, which may have limited our ability to demonstrate more subtle differences between some of the groups. We were unable to time sample collection precisely in the menstrual cycle in women on LNG-IUS because the majority of cycles were anovulatory, although our sensitivity analysis indicated that ovulatory status did not affect the results. The failure to find differences between the cervical transcriptomes could be due to the timing of sample collection in the luteal phase, when the hormonal and/or contraceptive effects would be predicted to be have produced unfavorable mucus in all groups. Finally, the cu-IUD is not a perfect comparator to the LNG-IUS: the ideal comparison would be the same IUD with and without LNG, and an ideal comparator to the LNG-IUS group would be locally applied rather than systemic LNG. Nevertheless, our findings, particularly with respect to differences in IUD groups, indicate a strong effect of local LNG on gene expression in the endometrium.

In summary, our results demonstrate that the LNG-IUS and cu-IUD differ significantly in their effects on the endometrial transcriptome. Whereas the LNG-IUS induces many changes in immune and inflammatory genes and pathways, endometrium from cu-IUD users is indistinguishable from the luteal phase endometrium in the control group. These results suggest the presence of a foreign body per se has less effect on the endometrium than locally released LNG and argue against a foreign body reaction as a common mechanism of action of IUDs.
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